Core Viewpoint - Penumbra's stock experienced a significant increase of approximately 14% following the announcement of a deal on Thursday morning [1] Group 1 - The announcement of the deal positively impacted Penumbra's stock performance, indicating strong market reaction [1]

Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in ShenzhenLAS VEGAS, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) (“CBSC” or the “Company”), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, today provided an update on the execution of its China market entry plan for its MyCardia AT cardiac event monitoring device. The Company has formally initiated manufacturing and re ...

Transaction Overview - Boston Scientific announced a definitive agreement to acquire Penumbra, valuing the company at $374 per share[10] - The transaction consideration reflects a total equity value of $15 billion, funded by approximately $11 billion in cash and approximately $4 billion in Boston Scientific stock, resulting in a 73% cash, 27% stock mix[29] - The equity issuance is expected to be approximately 41 million shares, fixed at the time of signing based on Boston Scientific's 10-day VWAP ending January 13, 2026[29] - The transaction is expected to close in 2026, subject to Penumbra shareholder approval and customary closing conditions[28, 29] Penumbra Financials and Market Opportunity - Penumbra's Q4 2025 reported revenue growth is +21.4-22.0% compared to 2024[13] - Penumbra's FY25 reported revenue growth is +17.3-17.5% compared to 2024[13] - Penumbra's FY25E gross margin is 67.9-68.1% and operating margin is 13.3-13.6%[13] - Penumbra operates in large, underserved spaces including mechanical thrombectomy, embolization, and neurovascular segments[10] - The total annual U S opportunity includes 315,000+ peripheral patients and 175,000 MMAe patients[16] Strategic Rationale - The acquisition provides Boston Scientific with entry into new key segments with a WAMGR accretive to Boston Scientific[10] - The combination is expected to deliver meaningful revenue contribution and cost efficiencies, supporting long-range planning goals[10] - Penumbra has a WAMGR of approximately 11% in high-growth adjacent areas[18]

Integra LifeSciences used its update at the ongoing 2026 J.P. Morgan Healthcare Conference in San Francisco to frame 2025 and 2026 as a deliberate transition period. The company described a shift from disruption and remediation toward more predictable execution, supported by product relaunches, a more resilient supply chain, and reimbursement changes that could make parts of its wound portfolio more economically attractive in outpatient settings. Integra spent a meaningful portion of the presentation on ...

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce t ...

Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its fourth quarter earnings conference call on February 10, 2026, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1]. Group 1: Earnings Call Details - The earnings conference call will be accessible via a live audio webcast on Zimmer Biomet's Investor Relations website, with a replay available after the call [2]. - U.S. and Canada participants can join the call by dialing (800) 330-6710, while international callers should use +1 (213) 279-1505, both requiring conference ID 7090861 [2]. Group 2: Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, offering a comprehensive portfolio aimed at enhancing mobility and health [3]. - The company focuses on transforming patient experiences through innovative products and integrated digital and robotic technologies that utilize data analytics and artificial intelligence [3]. - With over 90 years of experience, Zimmer Biomet is committed to delivering high-quality solutions to patients and healthcare providers, reflecting a culture of evolution and innovation [4].

Group 1 - Boston Scientific has agreed to acquire Penumbra, a thrombectomy company, for approximately $15 billion in cash and stock [1] - This acquisition is aimed at strengthening Boston Scientific's cardiovascular portfolio [1]

Group 1 - Boston Scientific announced the acquisition of Penumbra for approximately $14.5 billion [1]

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction i MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a definitive agreement ...

Core Insights - BD has received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, which is set to launch in early 2026, marking a significant advancement in breast health technology [1][2]. Product Overview - The EnCor EnCompass™ Biopsy System is designed to enhance the breast biopsy experience by allowing clinicians to perform procedures across various breast imaging platforms using a single integrated system [2][5]. - Key features include multi-modality use, adjustable vacuum strengths, 360° sampling capability, enhanced visualization tools, and a choice of probe sizes (12G, 10G, and 7G) to accommodate different lesion types [7]. Company Commitment - BD emphasizes its commitment to developing patient-centered solutions that improve early detection and diagnosis of breast diseases, reflecting its ongoing focus on addressing the needs of clinicians and patients [2][3][5]. - The company aims to enhance the safety and efficiency of care delivery while supporting clinical processes through innovative technologies [6].